文献速递眼底病与葡萄膜炎小儿眼科与斜弱视

早产儿视网膜病变的病理生理、筛查与治疗:多学科视角

Pathophysiology, screening and treatment of ROP: A multi-disciplinary perspective.
PubMed 文献 · Prog Retin Eye Res · 2017-09-27

本文从多学科视角综述早产儿视网膜病变(ROP),指出不同地区高危婴儿人群不同:新生儿重症监护完善地区为出生胎龄<28周且出生体重<1 kg者,常规重症监护与眼科 care 不可及地区还包括出生体重达2000 g、胎龄达37周的较成熟婴儿。治疗包括标准视网膜激光光凝或较新的玻璃体腔抗VEGF药物。综述还强调远程医疗使非眼科医生可用数字眼底相机在偏远地区筛查和诊断ROP,并讨论抗VEGF治疗的风险与获益、新疗法及最佳新生儿护理方案。

要点

  • 新生儿重症监护完善地区ROP最高危者为出生胎龄<28周且出生体重<1 kg的婴儿。
  • 常规重症监护与眼科 care 不可及地区,出生体重达2000 g、胎龄达37周的较成熟婴儿也有严重ROP风险。
  • 治疗选择包括标准视网膜激光光凝或较新的玻璃体腔抗VEGF药物。

核心结论

  • 综述从多学科视角汇总ROP视网膜血管形成机制、发病机制、筛查与治疗、抗VEGF风险获益、新疗法、新生儿护理方案及远程医疗的益处与陷阱,这些均有可能改善ROP结局。

研究设计与样本

  • 综述由视网膜血管生物学家、小儿眼科医生、流行病学家和新生儿科医生共同撰写,采用多学科视角。

主要发现

  • 新生儿重症监护完善地区ROP最高危婴儿为出生胎龄<28周且出生体重<1 kg者。
  • 常规新生儿重症监护与眼科 care 不可及地区,出生体重达2000 g、胎龄达37周的较成熟婴儿也有严重ROP风险。
  • 远程医疗使非眼科医生可用数字眼底相机在偏远地点进行ROP筛查和诊断。

关键数值与推荐

  • 高危婴儿标准因地区而异:新生儿重症监护完善地区为出生胎龄<28周且出生体重<1 kg;常规监护与眼科 care 不可及地区还包括出生体重达2000 g、胎龄达37周者。

临床怎么用

  • 两组患者的治疗选择包括标准视网膜激光光凝或较新的玻璃体腔抗VEGF药物。
  • 筛查和诊断ROP可在偏远地点由非眼科医生使用数字眼底相机通过远程医疗完成。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The population of infants at risk for retinopathy of prematurity (ROP) varies by world region; in countries with well developed neonatal intensive care services, the highest risk infants are those born at less than 28 weeks gestational age (GA) and less than 1 kg at birth, while, in regions where many aspects of neonatal intensive and ophthalmological care are not routinely available, more mature infants up to 2000 g at birth and 37 weeks GA are also at risk for severe ROP. Treatment options for both groups of patients include standard retinal laser photocoagulation or, more recently, intravitreal anti-VEGF drugs. In addition to detection and treatment of ROP, this review highlights new opportunities created by telemedicine, where screening and diagnosis of ROP in remote locations can be undertaken by non-ophthalmologists using digital fundus cameras. The ophthalmological care of the ROP infant is undertaken in the wider context of neonatal care and general wellbeing of the infant. Because of this context, this review takes a multi-disciplinary perspective with contributions from retinal vascular biologists, pediatric ophthalmologists, an epidemiologist and a neonatologist. This review highlights the latest insights regarding cellular and molecular mechanisms in the formation of the retinal vasculature in the human infant, pathogenesis of ROP, detection and treatment of severe ROP, the risks and benefits of anti-VEGF therapy, the identification of new therapies over the horizon, and the optimal neonatal care regimen for best ROP outcomes, and the benefits and pitfalls of telemedicine in the remote screening and diagnosis of ROP, all of which have the potential to improve ROP outcomes.

来源:Prog Retin Eye Res,查看原文。版权归原作者所有。

引用

  1. Chan-Ling T, Gole GA, Quinn GE, et al. Pathophysiology, screening and treatment of ROP: A multi-disciplinary perspective. Prog Retin Eye Res. 2017. PMID: 28958885. doi:10.1016/j.preteyeres.2017.09.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。